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can’t expect to get a patent for a spring clip mousetrap 
since they have been around for centuries, that is, there 
is “prior art” regarding the idea on which the trap is based. 
You can manufacture your new trap, but you can’t have 
a monopoly on it.
There are two keys to a patent: the first is novelty, the 
absence of prior art, and the second is disclosure. That is, 
the clever idea you have come up with (using plant x for 
disease y) must be published, and cannot be held secretly. 
The historical justification for this quid pro quo, enunciated 
centuries ago by Thomas Jefferson, among others, was 
that the purpose of granting monopolies was to “Promote 
the progress of science and useful arts, by securing 
for limited times to authors and inventors the exclusive 
right to their respective writings and discoveries” (US 
Constitution, I.8.8, 1787). Hence, copyright and patent. 
Of course, the point of copyright is to protect written work, 
but it wouldn’t make much sense (or “promote” much of 
anything) if one kept his writing secret. And, the quid pro 
quo for a patent is the obligation to disclose the nature of 
the invention (the word “patent” is derived from the Latin 
patere, “to lay open.”) 
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As an anthropologist, I have had to learn a good deal 
about botany (and particularly about botanists) to edit 
Economic Botany. One thing I’ve learned is that botanists 
are mighty prickly sticklers (one might describe them as 
rosaceous) when it comes to the details of plant names. 
Genus and species must be properly spelled, in italics, and 
authorities must be given with the proper abbreviations. 
When this isn’t done exactly right, people get, well, sharp. 
And voucher specimens are de rigeur; without them, you 
just don’t have anything. After all, without a voucher, how 
can we be sure what you are talking about?
There is one exception to all this. It occasionally happens 
that I will receive a paper all about the human uses of 
plants, with no plant names at all, or sometimes, with half 
the plants named, but not the other half. Such obfuscation 
is not an error, or an oversight, but deliberate. It usually 
(but not always) happens with plants used medicinally. 
And it is also usually the end result of some sort of ethical 
policy designed to protect the intellectual property rights 
of a group of informants who may thereby somehow profit 
financially from the development of a drug to cure cancer 
or AIDS. While it is occasionally done openly and with a 
bold explanation, occasionally it is done more furtively, as 
if no one might notice.
One version of this practice is that authors decide only 
to identify plants that have already been named in the 
botanical literature as having some sort of use similar to, 
or the same as, the one about which they have learned. 
This suggests that there is some sort of understanding of 
ownership (the “property” part of the equation) at play.
This might be reasonable by analogy to the notion of “prior 
art” in patent law. Note that I am not a lawyer, and I may 
be stretching the analogies here. Regardless, the key to 
prior art is that, in ordinary patent law, one can’t patent 
something that someone else has already developed. One 
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Jefferson and other progressive thinkers realized that 
the key to development of knowledge was openness, not 
secrecy. I contend that an approach to plant knowledge 
based on secrecy is wrong and damaging, and should 
never be entered into by any scientist unless it is absolutely 
necessary.
Consider some of the unintended consequences of 
secrecy. Suppose Louise goes to the Huggermuggers, and 
finds that Alpha beta Moerman, used for shingles, is not in 
the literature. Now, it’s hard to know how she knows that 
since, of course, it’s essentially not in the literature she is 
familiar with. It could be published in some source written in 
Swahili, or Romanian or Hindi. But suppose Louise is very 
well read, and it really truly isn’t published anywhere. The 
inference is that no other native group uses it, so it is truly 
a use without “prior art.” So, she publishes an article about 
the wisdom of the Huggermuggers, obscuring somehow 
the use of Alpha beta for shingles, and, in the process, 
obscuring the voucher sheet back at the herbarium.
Six months later, Jim shows up to do research with the 
Hongerpungers, neighbors in the next county to Louise’s 
group. He finds that Alpha beta is used to treat shingles. 
He doesn’t find it in the literature, and so he publishes 
some blah blah, obscuring the use of A.b. for shingles.
Repeat several times.
Now we have 5 different groups under the misapprehension 
that they are the sole owners of valuable intellectual 
property regarding Alpha beta and shingles.
It’s also the case that no one with the know how or 
experience to determine if A.b. actually does have any 
action against Varicella zoster, and how it might be utilized 
to their benefit (or to any of the people who presumably 
discovered this information) knows about A.b. And if one 
did find out somehow about one of these cases (by some 
ethnobotanist presumably breaking his vow of silence, 
i.e., creating a serious ethical gaffe) then we could expect 
that the four others, sooner or later, would be really 
really annoyed, although I don’t know what they could be 
annoyed about, given that they were advised to keep their 
knowledge secret, which they did.
Note that the relevant issue here, the justification for 
patent law, grants a short term monopoly (17 to 20 years 
is typical) to the discoverer of something presumably 
useful if the secret, discovery, and creation, is publicly 
shared, minimally in the United States by publication in 
the Patent Gazette (now online for all to see at uspto.gov; 
details vary by country).
So secrecy is, generally, the antithesis of protection. 
There are exceptions, like trade secrets, for example, the 
formula for Coca Cola®. But that hasn’t stopped dozens 
of other companies from coming up with essentially 
undistinguishable products. (I once heard the president 
of Coca Cola say “It’s not hard to make a soft drink. The 
challenge is to sell 2 billion glasses of it a day.”)
I don’t think this “don’t publish it unless it’s already been 
published” trick really works. I think it is a bad idea. 
Suppose Fleming, the discoverer of penicillin said, “Well, 
this is for my culture, and no one else can use it. I’ll just 
allow it to be used by fellow Scots. For anyone else, it’s 
a secret.” (Fortunately, it didn’t work out that way; I just 
found an Internet site offering penicillin tablets for 40 cents 
a piece.) Unfortunately, sometimes governments require 
such secrecy as the price of doing research. Likely, the 
relevant actors have a highly inflated notion of what these 
secrets are worth (learned, probably, from exaggerating 
ethnobotanists, although that term may be redundant). 
Perhaps such places simply should not be research 
sites.
Reiterating, secrecy (think “classified documents”) is always 
a bad thing, or at least it always has bad consequences 
(even if it may have some good consequences, too, on 
occasion). Transparency is almost always good, but it 
may have some bad consequences, too (consider Elliot 
Spitzer; although if you look carefully, what ultimately did 
him in was his attempt to conceal, to keep secret, his 
expenditures.)
I maintain that a) any ethical arrangement involving 
secrecy is bound to have a bad result sooner or later, and 
hence should be avoided whenever possible, and b), in 
ethnobotany, it is best to assume before the fact that there 
is always prior art, even if you can’t find any evidence of 
it. (Absense of evidence is no proof.) It is always best to 
assume that others know this “fact” (x is used to cure y). 
Anyone who has ever read more than one list of useful 
plants knows that they inevitably seem to overlap by 
about half. Read one more and they all overlap by about 
two thirds. Keep reading, and there is no such thing as an 
“endemic” (as in “endemic knowledge.”) This seems to me 
to be the basis for a rich and important ethical principle.
